Trials / Withdrawn
WithdrawnNCT01830101
A Phase III Study of Re-Irradiation in Recurrent Glioblastoma
A Randomized Phase III Study of Re-Irradiation in Recurrent Glioblastoma
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- AHS Cancer Control Alberta · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators hope to improve overall median survival of patients with recurrent Glioblastoma by investigating continuous low-dose daily Temozolomide plus or minus five treatments of re-irradiation.
Detailed description
This is a stratified study for patients with recurrent intracranial glioblastoma or gliosarcoma previously treated with concurrent chemoradiation presenting radiographic progression or recurrence of tumour. Patients are stratified by extent of resection, time to re-irradiation and re-irradiation volume.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TMZ plus concurrent re-irradiation | |
| DRUG | Temozolomide | low-dose temozolomide daily for one year |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2015-05-01
- Completion
- 2017-11-01
- First posted
- 2013-04-12
- Last updated
- 2016-03-16
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT01830101. Inclusion in this directory is not an endorsement.